Menu Search
Equities

Shanghai Allist Pharmaceuticals Co Ltd

688578:SHH

Shanghai Allist Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)40.98
  • Today's Change-1.37 / -3.23%
  • Shares traded4.46m
  • 1 Year change+21.71%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai Allist Pharmaceuticals Co Ltd grew revenues 155.14% from 791.00m to 2.02bn while net income improved 393.54% from 130.52m to 644.17m.
Gross margin94.47%
Net profit margin38.37%
Operating margin40.42%
Return on assets25.24%
Return on equity27.50%
Return on investment27.43%
More ▼

Cash flow in CNYView more

In 2023, Shanghai Allist Pharmaceuticals Co Ltd increased its cash reserves by 244.40%, or 769.55m. The company earned 674.65m from its operations for a Cash Flow Margin of 33.43%. In addition the company generated 92.75m cash from investing, though they paid out 2.21m more in financing than they received.
Cash flow per share--
Price/Cash flow per share--
Book value per share10.03
Tangible book value per share9.88
More ▼

Balance sheet in CNYView more

Shanghai Allist Pharmaceuticals Co Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio7.97
Quick ratio7.88
Total debt/total equity0.0003
Total debt/total capital0.0003
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.